Key facts
- Pharmacelera’s last known valuation is $9.2M (May 2021).
- It has raised $9.0M; the latest was Later Stage VC ($7.1M) in Feb 2026.
- Notable investors include European Innovation Council, Inveready Asset Management, General Inception, Clave Capital, AVANÇSA — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Pharmacelera
- ·The full record, as it builds
Funding rounds
No funding rounds for Pharmacelera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pharmacelera
Developer of a drug discovery platform designed to explore large and diverse chemical spaces. The company's platform uses a 3D representation of molecules based on electrostatic, steric and hydrophobic interaction fields derived from semi-empirical quantum-mechanics calculations, enabling bioinformaticians and medicinal chemists to obtain results using benchmarked technology and boost their drug discovery projects.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2011
- Employees
- 24
- Website
- pharmacelera.com/
- Ownership
- Privately Held (backing)
Pharmacelera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pharmacelera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pharmacelera in its N-PORT filings yet. We sweep new filings monthly.